Sort by

Send to

Choose Destination

Links from Books

Items: 17


Update of the drug resistance mutations in HIV-1: Fall 2005.

Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.

Top HIV Med. 2005 Oct-Nov;13(4):125-31.


Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR.

Clin Infect Dis. 2005 Jul 15;41(2):236-42.


Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA 3rd, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR; AIDS Clinical Trials Group Study A5095 Team..

N Engl J Med. 2004 Apr 29;350(18):1850-61.


Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Gallant JE, Gerondelis PZ, Wainberg MA, Shulman NS, Haubrich RH, St Clair M, Lanier ER, Hellmann NS, Richman DD.

Antivir Ther. 2003 Dec;8(6):489-506. Review.


Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Gonzales MJ, Johnson E, Dupnik KM, Imamichi T, Shafer RW.

J Acquir Immune Defic Syndr. 2003 Dec 1;34(4):398-402.


Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.

Stoeckli TC, MaWhinney S, Uy J, Duan C, Lu J, Shugarts D, Kuritzkes DR.

Antimicrob Agents Chemother. 2002 Dec;46(12):4000-3.


Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.

Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F, Molina JM.

J Infect Dis. 2001 Sep 15;184(6):781-4.


Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.

Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Brown AJ, Savara AV, Hazelwood JD, D'Aquila RT.

J Infect Dis. 2000 Mar;181(3):904-11.


HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.

Miller V, Ait-Khaled M, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G, Tisdale M.

AIDS. 2000 Jan 28;14(2):163-71.


Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy BM, Arnold E, Yarchoan R, et al.

Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398-402.


Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC.

Ann Intern Med. 1994 Aug 15;121(4):263-8.


Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.

Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M.

N Engl J Med. 1995 Dec 21;333(25):1662-9.

Items per page

Supplemental Content

Support Center